Evaluation of MCT1, MCT4 and CD147 Genes in Peripheral Blood Cells of Breast Cancer Patients and Their Potential Use as Diagnostic and Prognostic Markers
Abstract
:1. Introduction
2. Results
2.1. Expression Characterization of MCT1, MCT4 and CD147 in Tumor Samples
2.2. Expression of the Markers in Serial Collection of Peripheral Blood: Potential Use in Diagnosis
2.3. Profile of MCT1, MCT4 and CD147 Expressions in Patients with Cancer Throughout Treatment: Potential Use as Prognosis Markers
2.4. MCT1, MCT4 and CD147 Expressions in MCF7 Cells as Laboratory Parameter
3. Discussion
4. Material and Methods
4.1. Patients
4.2. Total RNA Extraction from Peripheral Blood
4.3. RNA Extraction from Paraffin-Embedded Material
4.4. cDNA Synthesis
4.5. qPCR
4.6. Gene Expression Analysis
4.7. Statistical Analysis
5. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Weigelt, B.; Peterse, J.L.; van’t Veer, L.J. Breast cancer metastasis: Markers and models. Nat. Rev. 2005, 5, 591–602. [Google Scholar] [CrossRef] [PubMed]
- Hirata, B.K.B.; Oda, J.M.M.; Guembatovski, R.L.; Ariza, C.B.; Oliveira, C.R.C.; Watanabe, M.A.E. Molecular markers for breast cancer: Prediction on tumor behavior. Dis. Markers 2014, 513158. [Google Scholar] [CrossRef]
- Luporsi, E.; André, F.; Spyratos, F.; Martin, P.M.; Jacquemier, J.; Penault-Llorca, F.; Tubiana-Mathieu, N.; Sigal-Zafrani, B.; Arnould, L.; Gompel, A.; et al. Ki-67: Level of evidence and methodological considerations for its role in the clinical management of breast cancer: Analytical and critical review. Breast Cancer Res. Treat. 2012, 132, 895–915. [Google Scholar] [CrossRef] [PubMed]
- Jäger, W.; Eibner, K.; Löffler, B.; Gleixner, S.; Kräner, S. Serial CEA and CA a5-3 measurements during follow-up of breast cancer patients. Anticancer Res. 2000, 20, 5179–5182. [Google Scholar] [PubMed]
- Swietach, P.; Vaughan-Jones, R.D.; Harris, A.L. Regulation of Tumor pH and the Role of Carbonic Anhydrase 9. Cancer Metastasis Rev. 2007, 26, 299–310. [Google Scholar] [CrossRef] [PubMed]
- Lunt, L.Y.; Vander Heiden, M.G. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 2011, 27, 441–464. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pinheiro, C.; Longatto-Filho, A.; Scapulatempo, C.; Ferreira, L.; Martins, S.; Pellerin, L. Increased Expression of Monocarboxylate Transporters 1, 2, and 4 in Colorectal Carcinomas. Virchows Arch. 2008, 452, 139–146. [Google Scholar] [CrossRef] [PubMed]
- Halestrap, A.P.; Price, N.T. The proton-linked monocarboxilate transporter (MCT) family: Structure, function and regulation. Biochem. J. 1999, 343, 281–299. [Google Scholar] [CrossRef] [PubMed]
- Pinheiro, C.; Longatto-Filho, A.; Azevedo-Silva, J.; Casal, M.; Schmitt, F.C.; Baltazar, F. Role of monocarboxylate transporter in human cancers: State of the art. J. Bioenerg. Biomembr. 2012, 44, 127–139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Porporato, P.E.; Dhup, S.; Dadhich, R.K.; Copetti, T.; Sonveaux, P. Anticancer targets in the glycolytic metabolism of tumors: A comprehensive review. Front. Pharmacol. 2011, 2, 49. [Google Scholar] [CrossRef] [PubMed]
- Halestrap, A.P.; Meredith, D. The SLC16 Gene Family-from Monocarboxylate Transporters (MCTs) to Aromatic Amino Acid Transporters and beyond. Pflug. Arch. 2004, 447, 619–628. [Google Scholar] [CrossRef] [PubMed]
- Fang, J.; Quinones, Q.J.; Holman, T.L.; Morowitz, M.J.; Wang, Q.; Zhao, H.; Sivo, F.; Maris, J.M.; Wahl, M.L. The H+-Linked Monocarboxylate Transporter (MCT1/SLC16A1): A Potential Therapeutic Target for High-Risk Neuroblastoma. Mol. Pharmacol. 2006, 70, 2108–2115. [Google Scholar] [CrossRef] [PubMed]
- Froberg, M.K.; Gerhart, D.Z.; Enerson, B.E.; Manivel, C.; Guzman-Paz, M.; Seacotte, N.; Drewes, L.R. Expression of Monocarboxylate Transporter MCT1 in Normal and Neoplastic Human CNS Tissues. Neuroreport 2001, 12, 761–765. [Google Scholar] [CrossRef] [PubMed]
- Boidot, R.; Vegran, F.; Meulle, A.; Le Breton, A.; Dessy, C.; Sonveaux, P.; Lizard-Nacol, S.; Feron, O. Regulation of Monocarboxylate Transporter MCT1 Expression by p53 Mediates Inward and Outward Lactate Fluxes in Tumors. Cancer Res. 2012, 72, 939–948. [Google Scholar] [CrossRef] [PubMed]
- Pinheiro, C.; Penna, V.; Morais-Santos, F.; Abrahão-Machado, L.; Ribeiro, G.; Curcelli, E.; Olivieri, M.; Morini, S.; Valença, I.; Ribeiro, D.; et al. Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: Distinct prognostic impact of MCT1 sub-cellular localization. J. Transl. Med. 2014, 12, 118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bergersen, L.; Rafiki, A.; Ottersen, O.P. Immunogold Cytochemistry Identifies Specialized Membrane Domains for Monocarboxylate Transport in the Central Nervous System. Neurochem. Res. 2002, 27, 89–96. [Google Scholar] [CrossRef] [PubMed]
- Meredith, D.; Bell, P.; McClure, B.; Wilkins, R. Functional and Molecular Characterisation of Lactic Acid Transport in Bovine Articular Chondrocytes. Cell. Physiol. Biochem. 2002, 12, 227–234. [Google Scholar] [CrossRef] [PubMed]
- Weidle, U.H.; Scheuer, W.; Eggle, D.; Klostermann, S.; Stockinger, H. Cancer-related Issues of CD147. Cancer Genom. Proteom. 2010, 7, 157–170. [Google Scholar]
- Pinheiro, C.; Reis, R.M.; Ricardo, S.; Longatto-Filho, A.; Schmitt, F.; Baltazar, F. Expression of monocarboxylate transportes 1, 3 and 4 in human tumours and their association with CD147 and CD44. J. Biomed. Biotechnol. 2010. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schneiderhan, W.; Scheler, M.; Holzmann, K.H.; Marx, M.; Gschwend, J.E.; Buchholz, M.; Gress, T.M.; Adler, G.; Seufferlein, T.; Oswald, F. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 2009, 58, 1391–1398. [Google Scholar] [CrossRef] [PubMed]
- Gallagher, S.M.; Castorino, J.J.; Wang, D.; Philp, N.J. Monocarboxylate Transporter 4 Regulates Maturation and Trafficking of CD147 to the Plasma Membrane in the Metastatic Breast Cancer Cell Line MDA-MB-231. Cancer Res. 2007, 67, 4182–4189. [Google Scholar] [CrossRef] [PubMed]
- Diel, I.J.; Cote, R.J. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat. Rev. 2000, 26, 53–65. [Google Scholar] [CrossRef] [PubMed]
- Ring, A.; Smith, I.E.; Dowsett, M. Circulating tumour cells in breast cancer. Lancet Oncol. 2004, 5, 79–88. [Google Scholar] [CrossRef]
- Apostolaki, S.; Perraki, M.; Pallis, A.; Bozionelou, V.; Agelaki, S.; Kanellou, P.; Kotsakis, A.; Politaki, E.; Kalbakis, K.; Kalykaki, A.; et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I 27 and II breast cancer after the administration of adjuvant chemotherapy: Evaluation of their clinical relevance. Ann. Oncol. 2007, 18, 851–858. [Google Scholar] [CrossRef] [PubMed]
- Ignatiadis, M.; Perraki, M.; Apostolaki, S.; Politaki, E.; Xenidis, N.; Kafousi, M.; Stathopoulos, E.; Lianidou, E.; Sotiriou, C.; Georgoulias, V.; et al. Molecular detection and prognostic value of circulating cytokeratin—19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. Clin. Breast Cancer 2007, 7, 883–889. [Google Scholar] [CrossRef] [PubMed]
- Strati, A.; Markou, A.; Parisi, C.; Politaki, E.; Mavroudis, D.; Georgoulias, V.; Lianidou, E. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 2011, 11, 422. [Google Scholar] [CrossRef] [PubMed]
- Novaes, M.; Bendit, I.; Garicochea, B.; del Giglio, A. Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. Mol. Pathol. 1997, 50, 209–211. [Google Scholar] [CrossRef] [PubMed]
- Ma, M.; Zhu, H.; Zhang, C.; Sun, X.; Gao, X.; Chen, G. “Liquid biopsy”—ctDNA detection with great potencial and challenges. Ann. Transl. Med. 2015, 3, 235–241. [Google Scholar] [PubMed]
- Zhu, J.; Wu, Y.N.; Zhang, W.; Zhang, X.M.; Ding, X.; Li, H.Q.; Geng, M.; Xie, Z.Q.; Wu, H.M. Monocarboxylate Transporter 4 Facilitates Cell Proliferation and Migration and Is Associated with Poor Prognosis in Oral Squamous Cell Carcinoma Patients. PLoS ONE 2014, 9, e87904. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.; Choi, J.W.; Lee, J.H.; Kim, Y.S. Expression of lactate/H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: Immunohistochemical and The Cancer Genome Atlas data analyses. Hum. Pathol. 2015, 46, 104–112. [Google Scholar] [CrossRef] [PubMed]
- Choi, J.W.; Kim, Y.; Lee, J.H.; Kim, Y.S. Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder. Urology 2014, 84, 245.e9–245.e15. [Google Scholar] [CrossRef] [PubMed]
- Pinheiro, C.; Albergaria, A.; Paredes, J.; Sousa, B.; Dufloth, R.; Vieira, D.; Schmitt, F.; Baltazar, F. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 2010, 56, 860–867. [Google Scholar] [CrossRef] [PubMed]
- Bovenzi, C.D.; Hamilton, J.; Tassone, P.; Johnson, J.; Cognetti, D.M.; Luginbuhl, A.; Keane, W.M.; Zhan, T.; Tuluc, M.; Bar-Ad, V.; et al. Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis. BioMed Res. Int. 2015, 242437. [Google Scholar] [CrossRef] [PubMed]
- Peng, L.; Zhu, H.; Wang, J.; Sui, H.; Zhang, H.; Jin, C.; Li, L.; Xu, T.; Miao, R. miR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147. Mol. Cell. Biochem. 2015, 405, 73–79. [Google Scholar] [CrossRef] [PubMed]
- Aaroe, J.; Lindahl, T.; Dumeaux, V.; Saebo, S.; Tobin, D.; Hagen, N.; Skaane, P.; Lonneborg, A.; Sharma, P.; Borresen-Dale, A.L. Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res. 2010, 12, R7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- LaBreche, H.G.; Nevins, J.R.; Huang, E. Integrating fator analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors. BMC Med. Genom. 2011, 4, 61. [Google Scholar] [CrossRef] [PubMed]
- Untergasse, A.; Cutcutache, I.; Koressaar, T.; Ye, J.; Faircloth, B.C.; Remm, M.; Rozen, S.G. Primer3—New capabilities and interfaces. Nucleic Acids Res. 2012, 40, e115. [Google Scholar] [CrossRef] [PubMed]
- Pfaffl, M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29, e45. [Google Scholar] [CrossRef] [PubMed]
- Matos, L.L.; Suarez, E.R.; Theodoro, T.R.; Trufelli, D.C.; Melo, C.M.; Garcia, L.F.; Oliveira, O.C.G.; Matos, M.G.L.; Kanda, J.L.; Nader, H.B.; et al. The Profile of Heparanase Expression Distinguishes Differentiated Thyroid Carcinoma from Benign Neoplasms. PLoS ONE 2015, 10, e0141139. [Google Scholar] [CrossRef] [PubMed]
Characteristics | n | % |
---|---|---|
Clinical Stage | ||
0/I | 36 | 28.8 |
II | 59 | 47.2 |
III | 30 | 24.0 |
Progression | ||
Negative | 113 | 91.9 |
Positive | 10 | 8.1 |
Hormone Receptors Expression | ||
Negative | 33 | 26.8 |
Positive | 90 | 73.2 |
Estrogen Receptor | ||
Negative | 31 | 25.2 |
Positive | 92 | 74.8 |
Progesterone Receptor | ||
Negative | 51 | 41.5 |
Positive | 72 | 58.5 |
Her_ihc * | ||
Negative | 28 | 22.9 |
+/3+ | 39 | 32.0 |
++/3+ | 24 | 19.7 |
+++/3+ | 31 | 25.4 |
Median (p.25; p.75) | Min.; Max. | |
Age | 52.5 (47; 61) | 27; 78 |
Follow-up Time (months) | 28 (24.5; 32) | 4; 49 |
Gene | Difference in Expression (Fold Change) | |||
---|---|---|---|---|
Stage II versus 0/I | Stage III versus II | Stage III versus 0/I | p * | |
MCT1 | 0.65 (0.43–0.98) | 27.46 (18.12–41.62) | 17.78 (11.73–26.25) | 0.149 |
MCT4 | 7.12 (4.7–10.8) | 1.25 (0.67–2.32) | 8.89 (5.86–13.47) | 0.433 |
CD147 | 3.70 (3.23–4.26) | 1.84 (1.60–2.11) | 6.83 (5.95–7.85) | 0.050 |
Gene | Expression Difference (Fold Change) | p * |
---|---|---|
MCT1 | 10.54 (5.3–21.01) | <0.001 |
MCT4 | 4.07 (2.03–8.15) | 0.066 |
CD147 | 11.8 (5.13–27.10) | <0.001 |
Sample | Disease Status | MCT1 * | MCT4 * | CD147 * |
---|---|---|---|---|
Donor | Healthy | 0.02 (0.01–0.05) | 0.001 (0.0005–0.002) | 0.067 (0.063–0.072) |
Patient | Without Progression | 0.15 (0.08–0.28) | 0.003 (0.001–0.006) | 0.35 (0.32–0.37) |
With Progression | 0.58 (0.31–1.09) | 0.056 (0.03–0.08) | 0.65 (0.53–0.80) |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Luz, M.C.d.B.; Perez, M.M.; Azzalis, L.A.; Sousa, L.V.d.A.; Adami, F.; Fonseca, F.L.A.; Alves, B.D.C.A. Evaluation of MCT1, MCT4 and CD147 Genes in Peripheral Blood Cells of Breast Cancer Patients and Their Potential Use as Diagnostic and Prognostic Markers. Int. J. Mol. Sci. 2017, 18, 170. https://doi.org/10.3390/ijms18040170
Luz MCdB, Perez MM, Azzalis LA, Sousa LVdA, Adami F, Fonseca FLA, Alves BDCA. Evaluation of MCT1, MCT4 and CD147 Genes in Peripheral Blood Cells of Breast Cancer Patients and Their Potential Use as Diagnostic and Prognostic Markers. International Journal of Molecular Sciences. 2017; 18(4):170. https://doi.org/10.3390/ijms18040170
Chicago/Turabian StyleLuz, Maria Cláudia de B., Matheus M. Perez, Ligia A. Azzalis, Luiz Vinícius de A. Sousa, Fernando Adami, Fernando L. A. Fonseca, and Beatriz Da C. A. Alves. 2017. "Evaluation of MCT1, MCT4 and CD147 Genes in Peripheral Blood Cells of Breast Cancer Patients and Their Potential Use as Diagnostic and Prognostic Markers" International Journal of Molecular Sciences 18, no. 4: 170. https://doi.org/10.3390/ijms18040170